Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy

Sangamo BioSciences (SGMO) PT Raised to $6 at Wedbush

May 16, 2017 8:45 AM EDT

Wedbush raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $6.00 (from $4.00) while maintaining a Neutral rating. Analyst Liana Moussatos views Pfizer as a long-term positive for the Hemophilia A program.

Management reiterated plans to release clinical data from its SB-FIX for... More